PMID- 35557586
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 13
IP  - 2
DP  - 2022 Apr
TI  - Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with 
      S-1 and oxaliplatin combined with S-1 in the first-line treatment of advanced 
      gastric cancer: a cohort study.
PG  - 630-636
LID - 10.21037/jgo-22-279 [doi]
AB  - BACKGROUND: Single-drug albumin-bound paclitaxel is one of the standard 
      second-line treatments for advanced gastric cancer. Some clinical studies suggest 
      that albumin-bound paclitaxel combined with S-1 can be used in the first-line 
      treatment of gastric cancer. Both the two regimens have been commonly used in the 
      past few years. Which is more effective? What's the safety? METHODS: From 2016 to 
      2021, a total of 70 untreated patients with advanced gastric cancer were included 
      in our study. They all received at least two cycles of chemotherapy. Among them, 
      37 cases received standard S-1 and oxaliplatin (SOX) regimen, and 33 cases 
      received albumin-bound paclitaxel combined with S-1 (aTS) regimen. 
      Progression-free survival (PFS), overall survival (OS), objective response rate 
      (ORR), and adverse events (AEs) were analyzed. The OS and PFS curves were 
      estimated using the Kaplan-Meier method. RESULTS: The PFS of the aTS group was 
      higher than that of the SOX group (9.27 vs. 7.03 months; P=0.046), but there was 
      no significant difference in the OS between the two groups (19.2 vs. 12.5 months; 
      P=0.131). The ORR of the aTS group was higher than that of the SOX group, and the 
      side effects were tolerable. CONCLUSIONS: Both regimens can be applied to 
      advanced gastric cancer patients. Albumin-bound paclitaxel showed a higher ORR 
      and could effectively prolong PFS.
CI  - 2022 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Ma, Jian
AU  - Ma J
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Xiao, Min
AU  - Xiao M
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Li, Xiaoqian
AU  - Li X
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Zhao, Qiu
AU  - Zhao Q
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Ji, Wenjing
AU  - Ji W
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Ling, Yang
AU  - Ling Y
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
FAU - Yang, Quanliang
AU  - Yang Q
AD  - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC9086041
OTO - NOTNLM
OT  - Albumin-bound paclitaxel
OT  - S-1
OT  - advanced gastric cancer
OT  - first-line therapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jgo.amegroups.com/article/view/10.21037/jgo-22-279/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/14 06:01
PMCR- 2022/04/01
CRDT- 2022/05/13 18:05
PHST- 2022/03/07 00:00 [received]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/05/13 18:05 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/14 06:01 [medline]
PHST- 2022/04/01 00:00 [pmc-release]
AID - jgo-13-02-630 [pii]
AID - 10.21037/jgo-22-279 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2022 Apr;13(2):630-636. doi: 10.21037/jgo-22-279.